Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Wyeth off on Prempro data

WYE was off $11.94 (24%) to $37.30 on 50.5 million shares on Tuesday after the NIH discontinued a trial that used

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE